PROVETOP

Biotinylated Human EGFRVIII Protein

Catalog No: EGFRVIII-HB001

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human EGFRVIII Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Leu25-Ser378 (accession: NP_001333870.1).

Product Details

Molecular Aliases
ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2; EC2.7.10; EC2.7.10.1
Protein Length
Leu25-Ser378
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 41.6 kDa. Due to glycosylation, the protein migrates to 60-78 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
EGFRVIII-HB001 Bis-Tris-PAGE-white result

Biotinylated Human EGFRVIII on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
EGFRVIII-HB001 SEC-HPLC result

The purity of Biotinylated Human EGFRVIII is greater than 95% as determined by SEC-HPLC.

ELISA
EGFRVIII-HB001 ELISA result

Immobilized Biotinylated Human EGFRVIII, His Tag at 0.5μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-EGFR VIII Anitibody, hFc Tag with the EC50 of 14.7ng/ml determined by ELISA (QC Test).

Flow Cytometry
EGFRVIII-HB001 Flow-Cytometry result

Use Biotinylated Human EGFRVIII, His Tag protein to detect the expression rate of Anti-EGFRVIII-CAR positive cell. 293T cells and anti-EGFRVIII CAR-293T cells were incubated with Biotinylated human EGFR VIII-His Tag. Non-transfected 293T cells and Biotinylated protein control were used as negative control. SA-PE was used to evaluate the binding activity of Biotinylated Human EGFR VIII.

Background

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.

References

  1. Pedersen M W, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation Biological significance and potential target for anti-cancer therapy[J]. Annals of Oncology, 2001, 12(6):745-760.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support